Cytokinetics | CYTK - Equity Capital And Reserves


Cytokinetics reported $-826.57M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Arca Biopharma USD 486.72M 17.72M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Capricor Therapeutics USD 278.7M 27.09M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Exelixis USD 1.94B 225.57M Mar/2026
Geron USD 229.11M 3.24M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026